JPH0223526B2 - - Google Patents
Info
- Publication number
- JPH0223526B2 JPH0223526B2 JP54111623A JP11162379A JPH0223526B2 JP H0223526 B2 JPH0223526 B2 JP H0223526B2 JP 54111623 A JP54111623 A JP 54111623A JP 11162379 A JP11162379 A JP 11162379A JP H0223526 B2 JPH0223526 B2 JP H0223526B2
- Authority
- JP
- Japan
- Prior art keywords
- viscosity
- nhch
- mucin
- sputum
- reducing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 20
- 239000003638 chemical reducing agent Substances 0.000 claims description 10
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 description 27
- 208000024794 sputum Diseases 0.000 description 27
- 210000003802 sputum Anatomy 0.000 description 26
- 210000003097 mucus Anatomy 0.000 description 13
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- -1 mercapto compounds Chemical class 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 5
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229960004308 acetylcysteine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010053070 Glutathione Disulfide Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000718 radiation-protective agent Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- XGYCHIPEPHYUIH-UHFFFAOYSA-N 2-mdp Chemical compound C=1C=CC=CC=1C(O)(C(CN)C)C1=CC=CC=C1 XGYCHIPEPHYUIH-UHFFFAOYSA-N 0.000 description 1
- UFBPLMUNCVFBOH-UHFFFAOYSA-N 2-sulfanylethanimidamide Chemical class NC(=N)CS UFBPLMUNCVFBOH-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Description
æ¬çºæã¯ãåºä¹³åç©ã®ã ãã³ç²åºŠãæžå°ããã
ããã®ã ãã³ç²åºŠæžå°å€ã«é¢ããã ç²æ¶²ã®ç¶æ ãåŠçœ®ããããã®å ¬ç¥ã®æ¹æ³ã¯ãç²
液ãååšããäœã®å Žæã«äŸåããŠãããèè žç³»ã
è管ããã³ã²ç®¡ã®ç²æ¶²åç¶ã¯ãç²æ¶²ããã®æ£åžžãª
ééã«ããé€å»ãããã«ã¯ãã®ç²åºŠãé«ãããã®
ã§ãäžè¬ã«ãã®é€å»ã®ããã®å€ç§çæ段ãå¿ èŠãš
ãããŠããããç°ããšåŒã°ããåŒåžåšç³»ã®ç²æ¶²ã¯ã
ããã·ããããçšããçã®ããŸããŸã®æ段ã«ãã
åŠçœ®ãããŠãããåŒåžåšé害ãæ²»çããããã®ïŒ
ã€ã®å žåçãªæ¹æ³ã¯ãâã¢ã»ãã«ã·ã¹ãã€ã³ã®
ãšã¢ãŸãŒã«ãçšããããšã§ãããâã¢ã»ãã«ã·
ã¹ãã€ã³ã¯ç°ã®ç²åºŠãæžå°ãããäžã§æ¥µããŠæå¹
ã§ã¯ãããããã®è¬å€ãèºã®å°ããªéè·¯ã«å åã«
æŸåºããããšã¯äžå¯èœã§ã¯ãªãã«ããŠãéåžžã«å°
é£ã§ãããåŸã€ãŠãç°ã®ç²åºŠãæžå°ãããå¹æ
ã¯ãå åãªæŸåºãåŸããããã©ããã«ããã€ãŠã
ããå ããŠãâã¢ã»ãã«ã·ã¹ãã€ã³ã¯èè žãåŒ
åžåšã®ç²èã«åºæ¿ãäžããŠããŸãã ç°ç²åºŠäžæã®åé¡ã¯ãã®ãèæ§ç·ç¶çã®æ£è ã®
ç ç¶ãæªåãããŠããŸããå³ã¡ãç°ã®é«ç²åºŠã¯ã
åŒåžåšãèè žç³»ã®æž æµã«ãããŠããŸãããããã®
éšäœãžã®æ°äœããã³æ é€ç©ã®æŸåºã«ãããŠå°é£ã«
å°ããæŽã«ãæ°çå ã«ãããŠã¯ãç°åžžã«é«ç²åºŠã®
èè žç²æ¶²ã«ããè žéå¡çå矀ãè䟿æ§ã¬ã€ãŠã¹ãš
ããŠçããããç¥ããªããçŸåšã®ãšãããããã
ã®è žéå¡ãæ²»çããå¯äžã®æ¹æ³ã¯ãç©ççã«éå¡
ãåé€ãå€ç§çæ¹æ³ã§ããã åŸã€ãŠãå€ç§çæ段ãŸãã¯ãšã¢ãŸãŒã«åœ¢ã®è¬ã®
ãããããçšããã«ç²æ¶²åäŒãæ²»çããç²åºŠãæž
å°ãããæ¹æ³ãæãŸããŠããã åŸã€ãŠæ¬çºæã®ç®çã¯ãã ãã³æº¶æ¶²ã®ç²åºŠãæž
å°ãããããã®è¬å€ãæäŸããããšã«ããã æŽã«æ¬çºæã®ç®çã¯ãç°ããã³ç²æ¶²ã®ç²åºŠã®æž
å°ã«ããåŒåžåšããã³èè žã®éå¡ãæ²»çããããš
ã«ããã æ¬çºæã®æŽã«ä»ã®ç®çã¯ãåºä¹³åç©ã«è¬å€ãçµ
å£æäžãŸãã¯éè泚å°ããããšã«ãããç°ã®ç²åºŠ
ãæžå°ãããããšã«ããã ãããæ¬çºæã®ç®çããã³ä»¥åŸæãããšãªãä»
ã®ç®çã¯ãçäœå ã§ã®ä»£å°ã«ããã¡ã«ã«ããåºã
å«ãååç©ãçæããååç©ãçµå£æäžãŸãã¯é
è泚å°ããããšã«ããéæãããã æ¬çºæã¯ãã®ãèæ§ç·ç¶çã®æ£è ã®ç°ãã
425000Dã®é«ååéãæããã ãã³ã®åé¢ã«åºã¥
ããã®ã§ããããã®ããçœè³ªã¯ããã®æ¿åºŠã®å¢å
ãç²åºŠã®äžæãããããã®ã§ãç°ã®ç²åºŠã®äžæã«
å¿çãåŸããæŽã«ãŸããçç°ã®å Žåã«ã¯ã粟補ã
ããã ãã³ã®ç²åºŠã¯ã¡ã«ã«ããæžå°å€ã«ããåŠç
ã«ããæžå°ãåŸããèºçãæ°ç®¡æ¯çã®æ£è ããåŸ
ãããç°ã«ãã€ãŠãåæ§ã®çµæãåŸããããç°ã
ãã³ç²åºŠã«å¯Ÿããæžå°å€ã®çååŠçå¹æã¯ãåå
ããæ®ãã©ã®çæ°Žåç©ãæããæåãšã65000ã
ãã³27000ïŒDAïŒTONSïŒã®ååéãæããïŒçš®
以äžã®ããããã«åå²ããããšã§ããããã®æ§é
ã®å€åã¯ååã®ã¬ãªããžãŒç¹æ§ã®æ¥æ¿ãªå€åãå°
ãããã®ååã®ã¬ãªããžãŒç¹æ§ã®å€åã¯éåžžã®ç
äœåå¿ã«ããç²æ¶²åæ³ãçäœèªèº«ãåé€ãããšã
å¯èœãšããã§ããããæ¬çºæè ãã¯ãã¡ã«ã«ãã
ååç©ã®äœ¿çšãç²æ¶²ç²åºŠãæžå°ãããäžã§éåžžã«
æå¹ã§ããããšãèŠåºããããåºä¹³åç©ãžã®ã¡ã«
ã«ããååç©ã®æœè¬ã¯ãéè泚å°ãŸãã¯çµå£æäž
ã«ããæœãããã¹ãã¡ã«ã«ããååç©ã«ãã€ãŠç²
液ãåŠçããæºè¶³ãã¹ãæ¹æ³ã§ããããšã¯èšŒæã
ããªãã€ããç¹ã«ãç²æ¶²ã®åæ³ãçããèºãä»ã®
åšå®ãžã®éäžã§ã®éé¢ããªãŒã«ãšè¡ããããèè ž
ã®ããçœè³ªãšã®åå¿ãè£åããããã«ãå€éã®ã¡
ã«ã«ããååç©ãäžããããã°ãªããªããããã
ãã®ããã«å€éã®ã¡ã«ã«ããååç©ã¯å¯äœçšãç
ããæãããããæ¬çºæè ãã¯ãç²æ¶²ç²åºŠãæžå°
ãããããã®ã¡ã«ã«ããååç©ã®æœè¬ã«äŒŽãªãå
é¡ããçäœå ã§ã¡ã«ã«ããåºã«å€æãããååç©
ãæäžããããšã«ãã解決ããåŸãããšãèŠåºã
ããé©åãªååç©ãšããŠã¯ã補è¬äžã§èªããããŠ
ããããªãµã«ããšãŒããããªãã¹ããšãŒãããžãµ
ã«ãã¢ã€ãçããããæ¬çºæã«ããã䜿çšã«é©å
ãªååç©ã¯ããã¹ãŠé®èœãããã¡ã«ã«ããåºãæ
ããããšã«ããç¹åŸŽã¥ããããŠããããã®ãããª
ååç©ã§ã¯é®èœå€ã¯çäœå ã§é€å»ãããŠã¡ã«ã«ã
ãåºã圢æãããé©åãªååç©ãšããŠãã¢ããã¢
ã«ãã«ããªç¡«é žãã¢ããã¢ã«ãã«ãã¹ããããªãš
ãŒããããªã¹ã«ãã¢ãã¢ã«ãã«ã¢ãã³ãããšãã«
ãã«ã¢ããã¢ã«ãã«ããªç¡«é žãããããã·ã¢ã«ã
ã«ã¢ããã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ãªã
ã·ã¢ããã¢ã«ãã«ããªç¡«é žãããšããã·ã¢ã«ãã«
ã¢ããã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ã¢ãã
ã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ã¢ã«ãã«ã¢ã
ãã¢ã«ãã«ããªãšãŒããã·ã¯ãã¢ã«ãã«ã¢ã«ãã«
ã¢ããã¢ã«ãã«ãžãµã«ãã¢ã€ããããšããã·ã¢ã«
ãã«ã¢ãããšãã«ãžãµã«ãã¢ã€ããããããã·ã¢
ã«ãã«ã¢ããã¢ã«ãã«ãžãµã«ãã¢ã€ããã¢ã«ãã«
ã¢ããžããŠã ããªãµã«ããšãŒããé®èœãããã¡ã«
ã«ããåºãå«ãã¢ã»ãã¢ããžã³èªå°äœãã¢ãªãŒã«
ã¢ã«ãã«ã¢ããžããŠã ããªãµã«ããšãŒããã¢ãã
ã¢ã«ãã«ã¢ããã¢ã«ãã«ãã¹ããããªãšãŒããã
ããªã«ãªãã·ã¢ã«ãã«ã¢ããã¢ã«ãã«ããªç¡«é žã
ããªãžã«ãªãã·ã¢ã«ãã«ã¢ããã¢ã«ãã«ããªç¡«
é žãããšããã·âããã³ããšãã«ããªã¢ã«ãã«ã¢
ããžããŠã ããªãµã«ããšãŒããã·ã¯ãã¢ã«ãã«ã¢
ããžããŠã ããªãµã«ããšãŒãçããããé®èœãã
ãã¡ã«ã«ããåºãçäœå ã§éé¢ã¡ã«ã«ããåºã«å€
æããããªãã°ãäžè¬ã«ã補è¬äžèªããããé®èœ
ãããã¡ã«ã«ããåºãå«ãã©ã®ãããªååç©ã§
ããæ¬çºæã«çšããããšãã§ãããã 以äžã®ååç©ã¯ãæ¬çºæã«çšããã«å¥œãŸããã
ã®ã§ããã ïŒ ïŒH2NCOCH2CH2NHCH2CH2SâïŒ2ã ïŒ H2NCOCH2CH2NHCH2CH2SSO3Hã ïŒ H2NCOCH2CH2NHCH2CH2SPO3H2ã ïŒ H2NïŒCH2ïŒ3NHCH2CH2SSO3Hã ïŒ ïŒH2NïŒCH2ïŒ3NHCH2CH2SâïŒ2ã ïŒ CH3ïŒCH2ïŒ9NHCH2CH2SSO3Hã ïŒ CH3ïŒCH2ïŒ9NHCH2CH2SPO3H2ã ïŒ ïŒCH3ïŒCH2ïŒ9NHCH2CH2SâïŒ2 ïŒ H2NCH2CH2SPO3H2ã 10 H2NïŒCH2ïŒ5NHïŒCH2ïŒ2SPO3H2ã 11 H2NïŒCH2ïŒ3NHïŒCH2ïŒ2SPO3H2 ãããã®ååç©ã®ãã¡ã§11ãç¹ã«å¥œãŸãããã
ã®ååç©ã¯ããŠãªã«ã¿ãŒãªãŒãã¢ãŒããŒã¡ãã€ã«
ã«ã»ã³ã¿ãŒïŒWalter Reed Army Medical
CenterïŒã«ãããŠå®æœãããæ¯æ§ãã¹ãã«ãã
ãŠWR2721ãšåã¥ãããããã®ã§ããããã®åå
ç©ã¯æ°èŠãªææŸå°ç·è¬ïŒantiradiationdrugïŒãš
ããŠææ¡ãããç±³åœç¹èš±ç¬¬3892824å·ã®äž»èŠéšã
ãªããã®ã§ããã æ¬çºæã®å®æœã«ãããŠãé®èœãããã¡ã«ã«ãã
åºãå«ãååç©ã¯ãã ãã³ç²åºŠãæžå°ãããã«å
åãªéãæ£è ã«æœããããæäžéã¯ãïŒæ¥ã«ã€ã
æ£è ã®äœéïŒKgãããïŒãªãã100mgãæºè¶³ãã¹
ãéã§ããããšãããã€ããæäžéã¯å¥œãŸããã¯
ïŒãªãã50mgïŒKgïŒæ¥ã§ãããç¹ã«å¥œãŸããæäž
éã¯ïŒmgïŒKgãïŒæ¥ã«ã€ãïŒåã§ããããã®åå
ç©ã¯ãé©åãªæ äœãšãšãã«çµå£æäžãŸãã¯éè泚
å°ã«ããæœããããéè泚å°ã¯ãã«ã«ããã·ã¡ã
ã«ã»ã«ããŒã¹ãããªãŠã ãå«ãããŸãã¯å«ãŸãªã
çççé£å¡©æ°Žããã³å¿ èŠãªãã°ããŠã€ãŒã³80ïŒå
ååïŒã䜿çšããããšãã§ããããŸãæããã«å
ã«çççé£å¡©æ°Žã®ã¿ãŸãã¯æ°Žã®ã¿ãšããããšãå¯
èœã§ããã 奜ãŸããæ¹æ³ã§ã¯ããã®ååç©ã¯é©ååºäœæ äœ
ãšãšãã«çµå£æäžããããå¿ èŠãªãã°ãç·©è¡å€ã®
ãããªè£å©è¬ãçšããããšãã§ãããè žè¢«èŠãæœ
ãããWR2721ãå«æããé å€ã®ãããªé©åãªé
å€åœ¢ã«æ圢ããŠãããããŸãããŒã©ãã³çã®é©å
ãªã«ãã»ã«ã®åœ¢ã§æœãããšãå¯èœã§ããã ç±³åœç¹èš±ç¬¬3892824ã¯ãäžè¿°ã®ååç©ã®æ¯æ§ã«
ã€ããŠå ±åããŠããããããã®ååç©ã«ã€ããŠè¡
ãªãããåç©å®éšã¯ã450mgïŒKgãªãã1300mgïŒ
Kgã®LD50ã瀺ããWR2721ãšããŠåå®ãããå
åç©ã«ã€ããŠã¯ããããã®æ¯æ§ãã¹ãã«ãããŠ
100mgïŒKgïŒæ¥ãŸã§ã®èŠåçãªæäžã«ãããŠæ¯æ§
ã®åé¡ã«ééããªãã€ããå¯èœæ§ã®ããWR2721
ã®å¯äœçšã«ã€ããŠããã¹ãã«ãããŠãèªçºçãªè¢«
è©Šéšè ã«100mgïŒKgïŒæ¥ã®æœè¬ãè¡ãªããããã
å¯äœçšã¯èªããããªãã€ãããã®çç±ãããåå
ç©WR2721ã¯ããããŸã§å®æœãããŠããææŸå°ç·
è¬ãšããŠã®çšéãšã®é¢é£ã«ãããåºç¯å²ã®èšåºã
ã¹ãããã¿ãŠã奜ãŸããååç©ã§ããã 以äžäžè¬çã«æ¬çºæãèšèŒãããã以äžã®å®æœ
äŸã«ãã€ãŠæŽãªãç解ãåŸãããã§ãããããªã
å®æœäŸã¯æ¬çºæãäŸç€ºãããã®ã§ãã€ãŠãäœãé
å®ãããã®ã§ã¯ãªã å®æœäŸ ïŒ ä»¥äžã®åå®æœäŸã«ãããŠã¯ã次ã®ç¥å·ãçšãã
ããã GSSGâŠâŠç°å ãããã°ã«ã¿ããªã³ GSHâŠâŠé žåãããã°ã«ã¿ããªã³ SDSâŠâŠããã·ã«ç¡«é žãããªãŠã DTEâŠâŠãžããªãšãªããªããŒã« DMSâŠâŠãžã¡ã«ã«ããã³ãã¯é ž MDPâŠâŠïŒ®âïŒâã¡ã«ã«ãããšãã«âïŒïŒïŒ
âãžã¢ãããããã³ çªçŽ é°å²æ°ã§ïŒåéïŒã¢ã«ã®HCläžã§WR2721
ã沞隰ãããããšã«ãã€ãŠMDPã補é ãããã
ã®æº¶æ¶²ãéçé žãããªãŠã ã§äžåãããæ ¢æ§ã®ã®
ãèæ§ç·ç¶çããã€ãïŒæã®ç·å ã®æ£è ãã姿å¢
æ液æ³ã«ããç°ãæ¡åããã泚å°å¯èœãªç¡«é žã²ã³
ã¿ãã·ã³ïŒgentamycin sulfateïŒ0.5mlãå容ã
ããžã€ãŒã«è©Šæãæ¡åãããããã«ïŒã¢ã«ã®ã¢ãž
åãããªãŠã 0.1mlãå ããè©Šææ¡åã®24æé以
å ã«åŠçããã ç°æåã®åé¢ããã³é»æ°æ°žåç¹æ§æ±ºå® å šäœã®ã®ãèæ§ç·ç¶çã®ç°ã®éšåæšæ¬10mlãã
0.1ã¢ã«ã®NaClãšïŒããªã¢ã«ã®ã¢ãžåãããªãŠã
ãå«ãçé žå¡©ç·©è¡æ¶²ïŒPH7.0ïŒã§å¹³è¡¡ãšãããã
ã€ãªã²ã«ïŒBiogelïŒA5MïŒBioRad瀟補ïŒã®ã³ã©
ã ïŒïŒÃ70cmïŒã«é©çšãããåãç·©è¡æ¶²ã§æº¶é¢ã
ããã空éã«çŸããç©è³ªãããŒã«ããŠæåãšå
ã¥ããã ãã€ãªã²ã«A5Mã«ããåé¢ã®åŸãæåã
0.8ïŒ0.5ããã³0.22ÎŒã®ãã€ã«ã¿ãŒïŒMillipore瀟
補ïŒã«é£ç¶çã«éãããã¯ããªã¢æ±æç©ãé€å»ã
ãã æåãïŒïŒïŒã€ã³ãåŸã®ç®¡ïŒSGA
Scientific瀟補ïŒã§ã®å®¹ééæã«ããïŒmlã«æ¿çž®
ããã次ãã§æçµæ¿åºŠã®ïŒïŒ SDSã«å ããããã
ãã®è©Šæã¯ãçªçŽ é°å²æ°äžã§0.1ã¢ã«ã®NaClãã
ã³ïŒïŒ SDSãå«ã0.01ã¢ã«ã®çé žå¡©ç·©è¡æ¶²ïŒPH
7.0ïŒ500mlã«ããã¢ãã³ã³ïŒAmiconïŒÃM100A
ãã€ã«ã¿ãŒïŒAmicon瀟補ïŒãä»ããŠæŽæµãã
ãããã€ã«ã¿ãŒã«æ®çããç©è³ªã¯æåãšåã¥
ããããåŸç¶ã®å®éšã§äœ¿çšããããç空éæã«ã
ãåæ¿çž®ãããã SDSâããªã¢ã¯ãªã«ã¢ããæåã²ã«é»æ°æ°žå
ïŒïŒãªãã16ïŒ ã¢ã¯ãªã«ã¢ããïŒããã€ãŒã«ã®æ¹
æ³ïŒMaizelïŒJ.V.ïŒ1971ïŒMethodsVirol.5ïŒ179
â246ïŒã«ããå®æœããããã²ã«ã¯ãã³ãŒãã·ãŒ
ïŒCoomassieïŒãã«ãŒïŒG.ïŒT.L.SteckïŒD.F.H.
WallachïŒïŒ1971ïŒBiochem.10ïŒ2606â2617ïŒãŸ
ãã¯éãšãŠçŽ é žâã·ããè©Šè¬ïŒZachariasïŒR.J.ïŒ
T.E.Ze11ïŒJ.H.MorrisonïŒJ.J.WoodlockïŒ
ïŒ1969ïŒAnal.Biochem.31ïŒ148â152ïŒã§çè²ã
ããã æåã®ç²Ÿè£œããã³ç¹æ§æ±ºå® SDSâããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åãæå
ã«ã€ããŠå®æœããããæåã®äž»æåã¯
425KDã®èŠããã®ååéãæããŠãããä»ã®å€
ãã®æåâãã®ïŒã€ïŒ65KDïŒã¯äž»èŠãªæ±æç©è³ª
ã§ãããâã¯ã¢ãã³ã³âSDSéæåŸãæ®çããã
ãããã®æ±æç©è³ªãé€å»ããåªåã¯æåããªãã€
ãã ç°å å€ã²ã«é»æ°æ³³åã«ããæåã®æŽãªãåŠ
çã¯ã65KDïŒ65000DAïŒTONSïŒããã³27KDã«
ãããŠå¹Ÿã€ãã®æ°ããã³ãŒãã·ãŒãã«ãŒçè²åž¯ã
瀺ãããä»ã®ã²ã«ã®PASçè²ãå ã®ã ãã³ãšå
ãé åã«ãããŠPASæ£åž¯ã瀺ããã®ã§ãããã
ã®ããããã¯æããã«å€§ããªååéã ãã³
ïŒ425KDïŒããå²ãããã®ã§ãã€ãã ç²åºŠæž¬å® ã¡ã«ã«ããåºã®æ·»å åãŸãã¯åŸã®çç°è©Šæã®ç²
床ãã0.08mlã®è©Šæã®æµãåºãã«èŠããæéã決
å®ããããšã«ãã0.2mlã®ããããã«ãããŠæž¬å®
ãããã粟補ãããã ãã³è©Šæãç空éæã«ãã
æ¿çž®ããã0.01ã¢ã«ã®çé žå¡©ç·©è¡æ¶²ïŒPH7.0ïŒã«
åããŠæ°æ¥ééæãããã次ãã§ããã¯ãã³äœåª
æå転ç²åºŠèšïŒã¢ãã«250010ïŒãçšããŠãã®ç²åºŠ
ã枬å®ãããããŸããŸã®æ¿åºŠã®ç·ç¶çŽ å溶液ã®ç²
床ãåæ§ã«æž¬å®ããããç²åºŠæž¬å®ã¯ãã¹ãŠå®€æž©äž
ã§å®æœããããïŒcmã¢ã«ã®DTEã®è¿œå ã«ããç²
床ã®å€åããïŒmlã®è©Šæã«500mlã®DET氎溶液
50λãå ããããšã«ãã枬å®ãããã ç°ãæåããã³æåã®ç²åºŠ ããçœè³ªæ¿åºŠãšç²åºŠãšã®é¢ä¿ããæåïŒïŒ¡
ããã³å€§ããªååéã®ç³ããçœè³ªã§ããç·ç¶çŽ å
ã«ã€ããŠç¬¬ïŒå³ã«ç€ºãããŠãããç°å šäœãæå
ããã³ïŒ¡ã«å¯ŸããïŒïœã¢ã«ã®DTEã®å¹æã第
ïŒå³ã«ç€ºãããŠãããäž¡æ¹ã®ç²Ÿè£œãããã ãã³æ
åã¯ãDTEã®æ·»å ã«å¯Ÿããç²åºŠã®å€åã«é¢ããŠ
ç°ãšåæ§ã®æåã瀺ãããªããå³äžãâ³ââ³ââ³
ã¯æåããâãâãã¯æåãâââââã¯
ç°å šäœãâ²ââ²ââ²ã¯ç·ç¶çŽ åã瀺ãã ããŸããŸã®è©Šè¬ã®æ·»å ã«å¯Ÿããç°ç²åºŠã®å€åã
è¡šã«ç€ºãããŠããããã¹ããããã¡ã«ã«ããå
åç©ã®äžã§ãDTEã¯çäœå ã«ãããŠæãæå¹ã§
ãã€ããé žåããã圢ã®ã°ã«ã¿ããªã³ãšãªãã€ã
ã¯é žã¯ããã®å¯Ÿå¿ããããªãŒã«ããã極ããŠæŽ»æ§
ãäœããé žåããããªãã€ãã¯é žã¯å šäœãšããŠç
äœå ã§ç°ã®ç²åºŠãæžå°ãããäžã§æå¹ã§ã¯ãªãã€
ããDTEã¯éå±ãã¬ãŒãå€ãšããŠäœçšããŠãã
ãããªã®ã§ãåæã®å ±åã®çµæãšããŠãé«æ¿åºŠã®
EDTAãç°ã®ç²åºŠãæžå°ãããããšãã§ããé
ã¡ã«ã«ãããã¬ãŒãå€ããã®ç³žã«ãããŠåæè©äŸ¡
ãããå¹æã®ãªãããšãããã€ãã ã®ãèæ§ç·ç¶çã®ç°ãžã®ïŒïœã¢ã«ã®MDPã®æ·»
å ã¯ã第ïŒå³ã«ç€ºãããã«15åéã§70ïŒ ã®ç²åºŠã
æžå°ãããããããã€ãŠã第ïŒå³ã®çµæãšèãå
ãããšãæåãæåã䞊ã³ã«ç°å šäœã«å¯Ÿã
ãŠãDTEããMDPã®æ¹ãåç°å¹æãçºæ®ããã
ãšãããããããšã®ããªãµã«ããšãŒã
ïŒWR2721ïŒã¯ç°ã®ç²åºŠã«å¯Ÿããå¹æããªãã€ãã
ããã®ã ãã³ç²åºŠæžå°å€ã«é¢ããã ç²æ¶²ã®ç¶æ ãåŠçœ®ããããã®å ¬ç¥ã®æ¹æ³ã¯ãç²
液ãååšããäœã®å Žæã«äŸåããŠãããèè žç³»ã
è管ããã³ã²ç®¡ã®ç²æ¶²åç¶ã¯ãç²æ¶²ããã®æ£åžžãª
ééã«ããé€å»ãããã«ã¯ãã®ç²åºŠãé«ãããã®
ã§ãäžè¬ã«ãã®é€å»ã®ããã®å€ç§çæ段ãå¿ èŠãš
ãããŠããããç°ããšåŒã°ããåŒåžåšç³»ã®ç²æ¶²ã¯ã
ããã·ããããçšããçã®ããŸããŸã®æ段ã«ãã
åŠçœ®ãããŠãããåŒåžåšé害ãæ²»çããããã®ïŒ
ã€ã®å žåçãªæ¹æ³ã¯ãâã¢ã»ãã«ã·ã¹ãã€ã³ã®
ãšã¢ãŸãŒã«ãçšããããšã§ãããâã¢ã»ãã«ã·
ã¹ãã€ã³ã¯ç°ã®ç²åºŠãæžå°ãããäžã§æ¥µããŠæå¹
ã§ã¯ãããããã®è¬å€ãèºã®å°ããªéè·¯ã«å åã«
æŸåºããããšã¯äžå¯èœã§ã¯ãªãã«ããŠãéåžžã«å°
é£ã§ãããåŸã€ãŠãç°ã®ç²åºŠãæžå°ãããå¹æ
ã¯ãå åãªæŸåºãåŸããããã©ããã«ããã€ãŠã
ããå ããŠãâã¢ã»ãã«ã·ã¹ãã€ã³ã¯èè žãåŒ
åžåšã®ç²èã«åºæ¿ãäžããŠããŸãã ç°ç²åºŠäžæã®åé¡ã¯ãã®ãèæ§ç·ç¶çã®æ£è ã®
ç ç¶ãæªåãããŠããŸããå³ã¡ãç°ã®é«ç²åºŠã¯ã
åŒåžåšãèè žç³»ã®æž æµã«ãããŠããŸãããããã®
éšäœãžã®æ°äœããã³æ é€ç©ã®æŸåºã«ãããŠå°é£ã«
å°ããæŽã«ãæ°çå ã«ãããŠã¯ãç°åžžã«é«ç²åºŠã®
èè žç²æ¶²ã«ããè žéå¡çå矀ãè䟿æ§ã¬ã€ãŠã¹ãš
ããŠçããããç¥ããªããçŸåšã®ãšãããããã
ã®è žéå¡ãæ²»çããå¯äžã®æ¹æ³ã¯ãç©ççã«éå¡
ãåé€ãå€ç§çæ¹æ³ã§ããã åŸã€ãŠãå€ç§çæ段ãŸãã¯ãšã¢ãŸãŒã«åœ¢ã®è¬ã®
ãããããçšããã«ç²æ¶²åäŒãæ²»çããç²åºŠãæž
å°ãããæ¹æ³ãæãŸããŠããã åŸã€ãŠæ¬çºæã®ç®çã¯ãã ãã³æº¶æ¶²ã®ç²åºŠãæž
å°ãããããã®è¬å€ãæäŸããããšã«ããã æŽã«æ¬çºæã®ç®çã¯ãç°ããã³ç²æ¶²ã®ç²åºŠã®æž
å°ã«ããåŒåžåšããã³èè žã®éå¡ãæ²»çããããš
ã«ããã æ¬çºæã®æŽã«ä»ã®ç®çã¯ãåºä¹³åç©ã«è¬å€ãçµ
å£æäžãŸãã¯éè泚å°ããããšã«ãããç°ã®ç²åºŠ
ãæžå°ãããããšã«ããã ãããæ¬çºæã®ç®çããã³ä»¥åŸæãããšãªãä»
ã®ç®çã¯ãçäœå ã§ã®ä»£å°ã«ããã¡ã«ã«ããåºã
å«ãååç©ãçæããååç©ãçµå£æäžãŸãã¯é
è泚å°ããããšã«ããéæãããã æ¬çºæã¯ãã®ãèæ§ç·ç¶çã®æ£è ã®ç°ãã
425000Dã®é«ååéãæããã ãã³ã®åé¢ã«åºã¥
ããã®ã§ããããã®ããçœè³ªã¯ããã®æ¿åºŠã®å¢å
ãç²åºŠã®äžæãããããã®ã§ãç°ã®ç²åºŠã®äžæã«
å¿çãåŸããæŽã«ãŸããçç°ã®å Žåã«ã¯ã粟補ã
ããã ãã³ã®ç²åºŠã¯ã¡ã«ã«ããæžå°å€ã«ããåŠç
ã«ããæžå°ãåŸããèºçãæ°ç®¡æ¯çã®æ£è ããåŸ
ãããç°ã«ãã€ãŠãåæ§ã®çµæãåŸããããç°ã
ãã³ç²åºŠã«å¯Ÿããæžå°å€ã®çååŠçå¹æã¯ãåå
ããæ®ãã©ã®çæ°Žåç©ãæããæåãšã65000ã
ãã³27000ïŒDAïŒTONSïŒã®ååéãæããïŒçš®
以äžã®ããããã«åå²ããããšã§ããããã®æ§é
ã®å€åã¯ååã®ã¬ãªããžãŒç¹æ§ã®æ¥æ¿ãªå€åãå°
ãããã®ååã®ã¬ãªããžãŒç¹æ§ã®å€åã¯éåžžã®ç
äœåå¿ã«ããç²æ¶²åæ³ãçäœèªèº«ãåé€ãããšã
å¯èœãšããã§ããããæ¬çºæè ãã¯ãã¡ã«ã«ãã
ååç©ã®äœ¿çšãç²æ¶²ç²åºŠãæžå°ãããäžã§éåžžã«
æå¹ã§ããããšãèŠåºããããåºä¹³åç©ãžã®ã¡ã«
ã«ããååç©ã®æœè¬ã¯ãéè泚å°ãŸãã¯çµå£æäž
ã«ããæœãããã¹ãã¡ã«ã«ããååç©ã«ãã€ãŠç²
液ãåŠçããæºè¶³ãã¹ãæ¹æ³ã§ããããšã¯èšŒæã
ããªãã€ããç¹ã«ãç²æ¶²ã®åæ³ãçããèºãä»ã®
åšå®ãžã®éäžã§ã®éé¢ããªãŒã«ãšè¡ããããèè ž
ã®ããçœè³ªãšã®åå¿ãè£åããããã«ãå€éã®ã¡
ã«ã«ããååç©ãäžããããã°ãªããªããããã
ãã®ããã«å€éã®ã¡ã«ã«ããååç©ã¯å¯äœçšãç
ããæãããããæ¬çºæè ãã¯ãç²æ¶²ç²åºŠãæžå°
ãããããã®ã¡ã«ã«ããååç©ã®æœè¬ã«äŒŽãªãå
é¡ããçäœå ã§ã¡ã«ã«ããåºã«å€æãããååç©
ãæäžããããšã«ãã解決ããåŸãããšãèŠåºã
ããé©åãªååç©ãšããŠã¯ã補è¬äžã§èªããããŠ
ããããªãµã«ããšãŒããããªãã¹ããšãŒãããžãµ
ã«ãã¢ã€ãçããããæ¬çºæã«ããã䜿çšã«é©å
ãªååç©ã¯ããã¹ãŠé®èœãããã¡ã«ã«ããåºãæ
ããããšã«ããç¹åŸŽã¥ããããŠããããã®ãããª
ååç©ã§ã¯é®èœå€ã¯çäœå ã§é€å»ãããŠã¡ã«ã«ã
ãåºã圢æãããé©åãªååç©ãšããŠãã¢ããã¢
ã«ãã«ããªç¡«é žãã¢ããã¢ã«ãã«ãã¹ããããªãš
ãŒããããªã¹ã«ãã¢ãã¢ã«ãã«ã¢ãã³ãããšãã«
ãã«ã¢ããã¢ã«ãã«ããªç¡«é žãããããã·ã¢ã«ã
ã«ã¢ããã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ãªã
ã·ã¢ããã¢ã«ãã«ããªç¡«é žãããšããã·ã¢ã«ãã«
ã¢ããã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ã¢ãã
ã¢ã«ãã«ããªç¡«é žãã·ã¯ãã¢ã«ãã«ã¢ã«ãã«ã¢ã
ãã¢ã«ãã«ããªãšãŒããã·ã¯ãã¢ã«ãã«ã¢ã«ãã«
ã¢ããã¢ã«ãã«ãžãµã«ãã¢ã€ããããšããã·ã¢ã«
ãã«ã¢ãããšãã«ãžãµã«ãã¢ã€ããããããã·ã¢
ã«ãã«ã¢ããã¢ã«ãã«ãžãµã«ãã¢ã€ããã¢ã«ãã«
ã¢ããžããŠã ããªãµã«ããšãŒããé®èœãããã¡ã«
ã«ããåºãå«ãã¢ã»ãã¢ããžã³èªå°äœãã¢ãªãŒã«
ã¢ã«ãã«ã¢ããžããŠã ããªãµã«ããšãŒããã¢ãã
ã¢ã«ãã«ã¢ããã¢ã«ãã«ãã¹ããããªãšãŒããã
ããªã«ãªãã·ã¢ã«ãã«ã¢ããã¢ã«ãã«ããªç¡«é žã
ããªãžã«ãªãã·ã¢ã«ãã«ã¢ããã¢ã«ãã«ããªç¡«
é žãããšããã·âããã³ããšãã«ããªã¢ã«ãã«ã¢
ããžããŠã ããªãµã«ããšãŒããã·ã¯ãã¢ã«ãã«ã¢
ããžããŠã ããªãµã«ããšãŒãçããããé®èœãã
ãã¡ã«ã«ããåºãçäœå ã§éé¢ã¡ã«ã«ããåºã«å€
æããããªãã°ãäžè¬ã«ã補è¬äžèªããããé®èœ
ãããã¡ã«ã«ããåºãå«ãã©ã®ãããªååç©ã§
ããæ¬çºæã«çšããããšãã§ãããã 以äžã®ååç©ã¯ãæ¬çºæã«çšããã«å¥œãŸããã
ã®ã§ããã ïŒ ïŒH2NCOCH2CH2NHCH2CH2SâïŒ2ã ïŒ H2NCOCH2CH2NHCH2CH2SSO3Hã ïŒ H2NCOCH2CH2NHCH2CH2SPO3H2ã ïŒ H2NïŒCH2ïŒ3NHCH2CH2SSO3Hã ïŒ ïŒH2NïŒCH2ïŒ3NHCH2CH2SâïŒ2ã ïŒ CH3ïŒCH2ïŒ9NHCH2CH2SSO3Hã ïŒ CH3ïŒCH2ïŒ9NHCH2CH2SPO3H2ã ïŒ ïŒCH3ïŒCH2ïŒ9NHCH2CH2SâïŒ2 ïŒ H2NCH2CH2SPO3H2ã 10 H2NïŒCH2ïŒ5NHïŒCH2ïŒ2SPO3H2ã 11 H2NïŒCH2ïŒ3NHïŒCH2ïŒ2SPO3H2 ãããã®ååç©ã®ãã¡ã§11ãç¹ã«å¥œãŸãããã
ã®ååç©ã¯ããŠãªã«ã¿ãŒãªãŒãã¢ãŒããŒã¡ãã€ã«
ã«ã»ã³ã¿ãŒïŒWalter Reed Army Medical
CenterïŒã«ãããŠå®æœãããæ¯æ§ãã¹ãã«ãã
ãŠWR2721ãšåã¥ãããããã®ã§ããããã®åå
ç©ã¯æ°èŠãªææŸå°ç·è¬ïŒantiradiationdrugïŒãš
ããŠææ¡ãããç±³åœç¹èš±ç¬¬3892824å·ã®äž»èŠéšã
ãªããã®ã§ããã æ¬çºæã®å®æœã«ãããŠãé®èœãããã¡ã«ã«ãã
åºãå«ãååç©ã¯ãã ãã³ç²åºŠãæžå°ãããã«å
åãªéãæ£è ã«æœããããæäžéã¯ãïŒæ¥ã«ã€ã
æ£è ã®äœéïŒKgãããïŒãªãã100mgãæºè¶³ãã¹
ãéã§ããããšãããã€ããæäžéã¯å¥œãŸããã¯
ïŒãªãã50mgïŒKgïŒæ¥ã§ãããç¹ã«å¥œãŸããæäž
éã¯ïŒmgïŒKgãïŒæ¥ã«ã€ãïŒåã§ããããã®åå
ç©ã¯ãé©åãªæ äœãšãšãã«çµå£æäžãŸãã¯éè泚
å°ã«ããæœããããéè泚å°ã¯ãã«ã«ããã·ã¡ã
ã«ã»ã«ããŒã¹ãããªãŠã ãå«ãããŸãã¯å«ãŸãªã
çççé£å¡©æ°Žããã³å¿ èŠãªãã°ããŠã€ãŒã³80ïŒå
ååïŒã䜿çšããããšãã§ããããŸãæããã«å
ã«çççé£å¡©æ°Žã®ã¿ãŸãã¯æ°Žã®ã¿ãšããããšãå¯
èœã§ããã 奜ãŸããæ¹æ³ã§ã¯ããã®ååç©ã¯é©ååºäœæ äœ
ãšãšãã«çµå£æäžããããå¿ èŠãªãã°ãç·©è¡å€ã®
ãããªè£å©è¬ãçšããããšãã§ãããè žè¢«èŠãæœ
ãããWR2721ãå«æããé å€ã®ãããªé©åãªé
å€åœ¢ã«æ圢ããŠãããããŸãããŒã©ãã³çã®é©å
ãªã«ãã»ã«ã®åœ¢ã§æœãããšãå¯èœã§ããã ç±³åœç¹èš±ç¬¬3892824ã¯ãäžè¿°ã®ååç©ã®æ¯æ§ã«
ã€ããŠå ±åããŠããããããã®ååç©ã«ã€ããŠè¡
ãªãããåç©å®éšã¯ã450mgïŒKgãªãã1300mgïŒ
Kgã®LD50ã瀺ããWR2721ãšããŠåå®ãããå
åç©ã«ã€ããŠã¯ããããã®æ¯æ§ãã¹ãã«ãããŠ
100mgïŒKgïŒæ¥ãŸã§ã®èŠåçãªæäžã«ãããŠæ¯æ§
ã®åé¡ã«ééããªãã€ããå¯èœæ§ã®ããWR2721
ã®å¯äœçšã«ã€ããŠããã¹ãã«ãããŠãèªçºçãªè¢«
è©Šéšè ã«100mgïŒKgïŒæ¥ã®æœè¬ãè¡ãªããããã
å¯äœçšã¯èªããããªãã€ãããã®çç±ãããåå
ç©WR2721ã¯ããããŸã§å®æœãããŠããææŸå°ç·
è¬ãšããŠã®çšéãšã®é¢é£ã«ãããåºç¯å²ã®èšåºã
ã¹ãããã¿ãŠã奜ãŸããååç©ã§ããã 以äžäžè¬çã«æ¬çºæãèšèŒãããã以äžã®å®æœ
äŸã«ãã€ãŠæŽãªãç解ãåŸãããã§ãããããªã
å®æœäŸã¯æ¬çºæãäŸç€ºãããã®ã§ãã€ãŠãäœãé
å®ãããã®ã§ã¯ãªã å®æœäŸ ïŒ ä»¥äžã®åå®æœäŸã«ãããŠã¯ã次ã®ç¥å·ãçšãã
ããã GSSGâŠâŠç°å ãããã°ã«ã¿ããªã³ GSHâŠâŠé žåãããã°ã«ã¿ããªã³ SDSâŠâŠããã·ã«ç¡«é žãããªãŠã DTEâŠâŠãžããªãšãªããªããŒã« DMSâŠâŠãžã¡ã«ã«ããã³ãã¯é ž MDPâŠâŠïŒ®âïŒâã¡ã«ã«ãããšãã«âïŒïŒïŒ
âãžã¢ãããããã³ çªçŽ é°å²æ°ã§ïŒåéïŒã¢ã«ã®HCläžã§WR2721
ã沞隰ãããããšã«ãã€ãŠMDPã補é ãããã
ã®æº¶æ¶²ãéçé žãããªãŠã ã§äžåãããæ ¢æ§ã®ã®
ãèæ§ç·ç¶çããã€ãïŒæã®ç·å ã®æ£è ãã姿å¢
æ液æ³ã«ããç°ãæ¡åããã泚å°å¯èœãªç¡«é žã²ã³
ã¿ãã·ã³ïŒgentamycin sulfateïŒ0.5mlãå容ã
ããžã€ãŒã«è©Šæãæ¡åãããããã«ïŒã¢ã«ã®ã¢ãž
åãããªãŠã 0.1mlãå ããè©Šææ¡åã®24æé以
å ã«åŠçããã ç°æåã®åé¢ããã³é»æ°æ°žåç¹æ§æ±ºå® å šäœã®ã®ãèæ§ç·ç¶çã®ç°ã®éšåæšæ¬10mlãã
0.1ã¢ã«ã®NaClãšïŒããªã¢ã«ã®ã¢ãžåãããªãŠã
ãå«ãçé žå¡©ç·©è¡æ¶²ïŒPH7.0ïŒã§å¹³è¡¡ãšãããã
ã€ãªã²ã«ïŒBiogelïŒA5MïŒBioRad瀟補ïŒã®ã³ã©
ã ïŒïŒÃ70cmïŒã«é©çšãããåãç·©è¡æ¶²ã§æº¶é¢ã
ããã空éã«çŸããç©è³ªãããŒã«ããŠæåãšå
ã¥ããã ãã€ãªã²ã«A5Mã«ããåé¢ã®åŸãæåã
0.8ïŒ0.5ããã³0.22ÎŒã®ãã€ã«ã¿ãŒïŒMillipore瀟
補ïŒã«é£ç¶çã«éãããã¯ããªã¢æ±æç©ãé€å»ã
ãã æåãïŒïŒïŒã€ã³ãåŸã®ç®¡ïŒSGA
Scientific瀟補ïŒã§ã®å®¹ééæã«ããïŒmlã«æ¿çž®
ããã次ãã§æçµæ¿åºŠã®ïŒïŒ SDSã«å ããããã
ãã®è©Šæã¯ãçªçŽ é°å²æ°äžã§0.1ã¢ã«ã®NaClãã
ã³ïŒïŒ SDSãå«ã0.01ã¢ã«ã®çé žå¡©ç·©è¡æ¶²ïŒPH
7.0ïŒ500mlã«ããã¢ãã³ã³ïŒAmiconïŒÃM100A
ãã€ã«ã¿ãŒïŒAmicon瀟補ïŒãä»ããŠæŽæµãã
ãããã€ã«ã¿ãŒã«æ®çããç©è³ªã¯æåãšåã¥
ããããåŸç¶ã®å®éšã§äœ¿çšããããç空éæã«ã
ãåæ¿çž®ãããã SDSâããªã¢ã¯ãªã«ã¢ããæåã²ã«é»æ°æ°žå
ïŒïŒãªãã16ïŒ ã¢ã¯ãªã«ã¢ããïŒããã€ãŒã«ã®æ¹
æ³ïŒMaizelïŒJ.V.ïŒ1971ïŒMethodsVirol.5ïŒ179
â246ïŒã«ããå®æœããããã²ã«ã¯ãã³ãŒãã·ãŒ
ïŒCoomassieïŒãã«ãŒïŒG.ïŒT.L.SteckïŒD.F.H.
WallachïŒïŒ1971ïŒBiochem.10ïŒ2606â2617ïŒãŸ
ãã¯éãšãŠçŽ é žâã·ããè©Šè¬ïŒZachariasïŒR.J.ïŒ
T.E.Ze11ïŒJ.H.MorrisonïŒJ.J.WoodlockïŒ
ïŒ1969ïŒAnal.Biochem.31ïŒ148â152ïŒã§çè²ã
ããã æåã®ç²Ÿè£œããã³ç¹æ§æ±ºå® SDSâããªã¢ã¯ãªã«ã¢ããã²ã«é»æ°æ³³åãæå
ã«ã€ããŠå®æœããããæåã®äž»æåã¯
425KDã®èŠããã®ååéãæããŠãããä»ã®å€
ãã®æåâãã®ïŒã€ïŒ65KDïŒã¯äž»èŠãªæ±æç©è³ª
ã§ãããâã¯ã¢ãã³ã³âSDSéæåŸãæ®çããã
ãããã®æ±æç©è³ªãé€å»ããåªåã¯æåããªãã€
ãã ç°å å€ã²ã«é»æ°æ³³åã«ããæåã®æŽãªãåŠ
çã¯ã65KDïŒ65000DAïŒTONSïŒããã³27KDã«
ãããŠå¹Ÿã€ãã®æ°ããã³ãŒãã·ãŒãã«ãŒçè²åž¯ã
瀺ãããä»ã®ã²ã«ã®PASçè²ãå ã®ã ãã³ãšå
ãé åã«ãããŠPASæ£åž¯ã瀺ããã®ã§ãããã
ã®ããããã¯æããã«å€§ããªååéã ãã³
ïŒ425KDïŒããå²ãããã®ã§ãã€ãã ç²åºŠæž¬å® ã¡ã«ã«ããåºã®æ·»å åãŸãã¯åŸã®çç°è©Šæã®ç²
床ãã0.08mlã®è©Šæã®æµãåºãã«èŠããæéã決
å®ããããšã«ãã0.2mlã®ããããã«ãããŠæž¬å®
ãããã粟補ãããã ãã³è©Šæãç空éæã«ãã
æ¿çž®ããã0.01ã¢ã«ã®çé žå¡©ç·©è¡æ¶²ïŒPH7.0ïŒã«
åããŠæ°æ¥ééæãããã次ãã§ããã¯ãã³äœåª
æå転ç²åºŠèšïŒã¢ãã«250010ïŒãçšããŠãã®ç²åºŠ
ã枬å®ãããããŸããŸã®æ¿åºŠã®ç·ç¶çŽ å溶液ã®ç²
床ãåæ§ã«æž¬å®ããããç²åºŠæž¬å®ã¯ãã¹ãŠå®€æž©äž
ã§å®æœããããïŒcmã¢ã«ã®DTEã®è¿œå ã«ããç²
床ã®å€åããïŒmlã®è©Šæã«500mlã®DET氎溶液
50λãå ããããšã«ãã枬å®ãããã ç°ãæåããã³æåã®ç²åºŠ ããçœè³ªæ¿åºŠãšç²åºŠãšã®é¢ä¿ããæåïŒïŒ¡
ããã³å€§ããªååéã®ç³ããçœè³ªã§ããç·ç¶çŽ å
ã«ã€ããŠç¬¬ïŒå³ã«ç€ºãããŠãããç°å šäœãæå
ããã³ïŒ¡ã«å¯ŸããïŒïœã¢ã«ã®DTEã®å¹æã第
ïŒå³ã«ç€ºãããŠãããäž¡æ¹ã®ç²Ÿè£œãããã ãã³æ
åã¯ãDTEã®æ·»å ã«å¯Ÿããç²åºŠã®å€åã«é¢ããŠ
ç°ãšåæ§ã®æåã瀺ãããªããå³äžãâ³ââ³ââ³
ã¯æåããâãâãã¯æåãâââââã¯
ç°å šäœãâ²ââ²ââ²ã¯ç·ç¶çŽ åã瀺ãã ããŸããŸã®è©Šè¬ã®æ·»å ã«å¯Ÿããç°ç²åºŠã®å€åã
è¡šã«ç€ºãããŠããããã¹ããããã¡ã«ã«ããå
åç©ã®äžã§ãDTEã¯çäœå ã«ãããŠæãæå¹ã§
ãã€ããé žåããã圢ã®ã°ã«ã¿ããªã³ãšãªãã€ã
ã¯é žã¯ããã®å¯Ÿå¿ããããªãŒã«ããã極ããŠæŽ»æ§
ãäœããé žåããããªãã€ãã¯é žã¯å šäœãšããŠç
äœå ã§ç°ã®ç²åºŠãæžå°ãããäžã§æå¹ã§ã¯ãªãã€
ããDTEã¯éå±ãã¬ãŒãå€ãšããŠäœçšããŠãã
ãããªã®ã§ãåæã®å ±åã®çµæãšããŠãé«æ¿åºŠã®
EDTAãç°ã®ç²åºŠãæžå°ãããããšãã§ããé
ã¡ã«ã«ãããã¬ãŒãå€ããã®ç³žã«ãããŠåæè©äŸ¡
ãããå¹æã®ãªãããšãããã€ãã ã®ãèæ§ç·ç¶çã®ç°ãžã®ïŒïœã¢ã«ã®MDPã®æ·»
å ã¯ã第ïŒå³ã«ç€ºãããã«15åéã§70ïŒ ã®ç²åºŠã
æžå°ãããããããã€ãŠã第ïŒå³ã®çµæãšèãå
ãããšãæåãæåã䞊ã³ã«ç°å šäœã«å¯Ÿã
ãŠãDTEããMDPã®æ¹ãåç°å¹æãçºæ®ããã
ãšãããããããšã®ããªãµã«ããšãŒã
ïŒWR2721ïŒã¯ç°ã®ç²åºŠã«å¯Ÿããå¹æããªãã€ãã
ãè¡šã
å®æœäŸ ïŒ
ããã¿ãžã®WR2721ã®éè泚å°ããã³çµå£æäž
åŸã®ããŸããŸãªçµéæéã§ã®äœçµç¹äžã®MDPæ¿
床ã決å®ããããïŒmlã®é£å¡©æ°Žäžã§ïŒåéæ¯ãã
ãšã«ãã€ãŠåŸãèºããã³èèã®åç質ãŸãã¯ïŒmm
ã®åãã®çµç¹ã®ã¹ã©ã€ã¹ãïŒmgïŒmlã®WR2721ã
çšããŠ37âã§å¹é€ããããMDPãžã®å€æã®è©äŸ¡
ã®ãããããŸããŸã®æéã«ãããéšåæšæ¬ãæ¡å
ããããCO2ã§ç ç²ã«ãããèºãé€å»ããããã
ã¿ã®çŒçª©åŸéšã®ç©¿åºã«ããè¡æ¶²ãåŸããããèºã
ãã³èèã®å質ç©ïŒé£å¡©æ°Žäž0.9ïŒ ïŒ·ïŒïŒ¶ïŒãã
ã³è¡æ¶²è©Šæãæçµæ¿åºŠ10ïŒ ãŸã§ããªã¯ããé ¢é žã§
åŠçãããïŒâã§10åéé眮ããããè©Šæã¯
3000rpmã§10åéé å¿åé¢ããããã®äžæŸæ¶²ãé
çé žãããªãŠã ã§äžåãããããããã®äžåãã
ãäžæŸæ¶²ã¯ã¡ã«ã«ããåºã®ååšã«ã€ããŠãšã«ãã³
ïŒEllman et alïŒã®æ¹æ³ïŒ1959幎Archã»
Biochem.Biophys.82ïŒ70â77ïŒã«ããåæè©äŸ¡
ãããã WR2721ã®ä»£è¬ã®ç 究 第ïŒå³ã«ç€ºãããã«ãWR2721ã¯ãçµå£æäžãŸ
ãã¯éè泚å°åŸã®ããã¿ã®è¡æ¶²äžã«éé¢ããªãŒã«
ãšããŠèªãããããããã¿ã®èºã®äžã®MDPã®åº
çŸã®æ©æ§ã¯ãçµå£æäžïŒå³ç€ºããªãïŒããã³éè
泚å°åŸã®è¡æ¶²ã«ã€ããŠãããšé¡äŒŒã§ããã WR2721ã®çµå£æäžã¯ãè¡æ¶²ããã³èºäžãžã®
MDPã®æ¥éãªåºçŸããããããäžæ¹ãéçµå£æ
äžã§ã¯24æéã«MDPã®åºçŸãã¿ãããã ïŒmgïŒmlã®WR2721ã§å¹é€ãããããã¿ã®èºã
èèããã³å°è žã®å質ç©ã¯ããã¹ãŠã®ååç©ã30
å以å ã«MDPã«å€æããããã®ããã«ããŠã
WR2721ã®ãã®æŽ»æ§éé¢ããªãŒã«èªå°äœãžã®å€æ
ã瀺ãããã ãã³ç²åºŠãæžå°ããããªãã第ïŒå³
ã«ãããŠãã¯50ïŒâ³ââ³ïŒã100ïŒãâãâãïŒã
ããã³200ïŒâââââïŒmgïŒKgã®WR2721ã®ãã
ã¿ãžã®éè泚å°åŸã®è¡æ¶²äžã®éé¢ã®ã¡ã«ã«ããã®
åºçŸã瀺ããã¯400mgïŒKgã®çµå£æäžåŸã®ãã
ã¿ã®è¡æ¶²äžã®éé¢ã®ã¡ã«ã«ããã®åºçŸã瀺ãã
ã¯200mgïŒKgã®éè泚å°åŸã®ããã¿ã®èºäžã®éé¢
ã®ã¡ã«ã«ããã®åºçŸã瀺ãã é²åŸ¡ãããã¡ã«ã«ããåºãå«ãååç©ã®æäž
ã¯ãéå°ã®ã ãã³ç²åºŠãååšããæ¡ä»¶ã®åŠçã«ã
ããŠçšããããšãã§ãããããã®ãããªæ¡ä»¶ãšã
ãŠã¯ãã®ãèæ§ç·ç¶çãèºçãæ°ç®¡æ¯çãããã
èè žç³»ã²èãèèçã®ã ãã³åç¶ããããã
åŸã®ããŸããŸãªçµéæéã§ã®äœçµç¹äžã®MDPæ¿
床ã決å®ããããïŒmlã®é£å¡©æ°Žäžã§ïŒåéæ¯ãã
ãšã«ãã€ãŠåŸãèºããã³èèã®åç質ãŸãã¯ïŒmm
ã®åãã®çµç¹ã®ã¹ã©ã€ã¹ãïŒmgïŒmlã®WR2721ã
çšããŠ37âã§å¹é€ããããMDPãžã®å€æã®è©äŸ¡
ã®ãããããŸããŸã®æéã«ãããéšåæšæ¬ãæ¡å
ããããCO2ã§ç ç²ã«ãããèºãé€å»ããããã
ã¿ã®çŒçª©åŸéšã®ç©¿åºã«ããè¡æ¶²ãåŸããããèºã
ãã³èèã®å質ç©ïŒé£å¡©æ°Žäž0.9ïŒ ïŒ·ïŒïŒ¶ïŒãã
ã³è¡æ¶²è©Šæãæçµæ¿åºŠ10ïŒ ãŸã§ããªã¯ããé ¢é žã§
åŠçãããïŒâã§10åéé眮ããããè©Šæã¯
3000rpmã§10åéé å¿åé¢ããããã®äžæŸæ¶²ãé
çé žãããªãŠã ã§äžåãããããããã®äžåãã
ãäžæŸæ¶²ã¯ã¡ã«ã«ããåºã®ååšã«ã€ããŠãšã«ãã³
ïŒEllman et alïŒã®æ¹æ³ïŒ1959幎Archã»
Biochem.Biophys.82ïŒ70â77ïŒã«ããåæè©äŸ¡
ãããã WR2721ã®ä»£è¬ã®ç 究 第ïŒå³ã«ç€ºãããã«ãWR2721ã¯ãçµå£æäžãŸ
ãã¯éè泚å°åŸã®ããã¿ã®è¡æ¶²äžã«éé¢ããªãŒã«
ãšããŠèªãããããããã¿ã®èºã®äžã®MDPã®åº
çŸã®æ©æ§ã¯ãçµå£æäžïŒå³ç€ºããªãïŒããã³éè
泚å°åŸã®è¡æ¶²ã«ã€ããŠãããšé¡äŒŒã§ããã WR2721ã®çµå£æäžã¯ãè¡æ¶²ããã³èºäžãžã®
MDPã®æ¥éãªåºçŸããããããäžæ¹ãéçµå£æ
äžã§ã¯24æéã«MDPã®åºçŸãã¿ãããã ïŒmgïŒmlã®WR2721ã§å¹é€ãããããã¿ã®èºã
èèããã³å°è žã®å質ç©ã¯ããã¹ãŠã®ååç©ã30
å以å ã«MDPã«å€æããããã®ããã«ããŠã
WR2721ã®ãã®æŽ»æ§éé¢ããªãŒã«èªå°äœãžã®å€æ
ã瀺ãããã ãã³ç²åºŠãæžå°ããããªãã第ïŒå³
ã«ãããŠãã¯50ïŒâ³ââ³ïŒã100ïŒãâãâãïŒã
ããã³200ïŒâââââïŒmgïŒKgã®WR2721ã®ãã
ã¿ãžã®éè泚å°åŸã®è¡æ¶²äžã®éé¢ã®ã¡ã«ã«ããã®
åºçŸã瀺ããã¯400mgïŒKgã®çµå£æäžåŸã®ãã
ã¿ã®è¡æ¶²äžã®éé¢ã®ã¡ã«ã«ããã®åºçŸã瀺ãã
ã¯200mgïŒKgã®éè泚å°åŸã®ããã¿ã®èºäžã®éé¢
ã®ã¡ã«ã«ããã®åºçŸã瀺ãã é²åŸ¡ãããã¡ã«ã«ããåºãå«ãååç©ã®æäž
ã¯ãéå°ã®ã ãã³ç²åºŠãååšããæ¡ä»¶ã®åŠçã«ã
ããŠçšããããšãã§ãããããã®ãããªæ¡ä»¶ãšã
ãŠã¯ãã®ãèæ§ç·ç¶çãèºçãæ°ç®¡æ¯çãããã
èè žç³»ã²èãèèçã®ã ãã³åç¶ããããã
第ïŒå³ã¯åè©Šæã®ããçœè³ªæ¿åºŠã«å¯Ÿããç²åºŠã®
å€åã瀺ãã°ã©ãã第ïŒå³ã¯DTEã®æ·»å ã«ãã
åè©Šæã®ç²åºŠã®å€åã瀺ãã°ã©ãã第ïŒå³ã¯
MDPæ·»å åŸã®ç°å šäœã®ç²åºŠã®å€åã瀺ãã°ã©ãã
ãããŠç¬¬ïŒå³ïŒ¡ïŒïŒ¢ïŒïŒ£ã¯ãWR2721ã®æäžåŸã®
éé¢ã¡ã«ã«ããåºã®åºçŸã瀺ãå³ã§ããã
å€åã瀺ãã°ã©ãã第ïŒå³ã¯DTEã®æ·»å ã«ãã
åè©Šæã®ç²åºŠã®å€åã瀺ãã°ã©ãã第ïŒå³ã¯
MDPæ·»å åŸã®ç°å šäœã®ç²åºŠã®å€åã瀺ãã°ã©ãã
ãããŠç¬¬ïŒå³ïŒ¡ïŒïŒ¢ïŒïŒ£ã¯ãWR2721ã®æäžåŸã®
éé¢ã¡ã«ã«ããåºã®åºçŸã瀺ãå³ã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ çäœå ã§ä»£è¬ã«ããå€æãããŠéé¢ã®ã¡ã«ã«
ããåºãšãªãé²åŸ¡ãããã¡ã«ã«ããåºãæããïŒ
çš®ãŸãã¯ãã以äžã®ååç©ãæå¹æåãšããæ²»ç
å¹æãæãã人äœäžã®ã ãã³ã®ç²åºŠãæžå°ããã
ããã®ã ãã³ç²åºŠæžå°å€ã ïŒ åèšé²åŸ¡ãããã¡ã«ã«ããåºãå«ãååç©
ã¯ã ïŒH2NCOCH2CH2NHCH2CH2SâïŒ2ã H2NCOCH2CH2NHCH2CH2SSO3Hã H2NCOCH2CH2NHCH2CH2SPO3H2ã H2NïŒCH2ïŒ3NHCH2CH2SSO3Hã ïŒH2NïŒCH2ïŒ3NHCH2CH2SâïŒ2ã CH3ïŒCH2ïŒ9NHCH2CH2SSO3Hã CH3ïŒCH2ïŒ9NHCH2CH2SPO3H2ã ïŒCH3ïŒCH2ïŒ9NHCH2CH2SâïŒ2 H2NCH2CH2SPO3H2ã H2NïŒCH2ïŒ5NHïŒCH2ïŒ2SPO3H2ã H2NïŒCH2ïŒ3NHïŒCH2ïŒ2SPO3H2ã ããã³ãã®æ²»çäžèš±å®¹ãããå¡©ãããªã矀ãã
éžæãããå°ãªããšãïŒçš®ã§ããè«æ±é ïŒèšèŒã®
ã ãã³ç²åºŠæžå°å€ã ïŒ æå¹æäžéã¯ïŒãªãã100mgïŒKgïŒæ¥ã§ãã
è«æ±é ïŒãŸãã¯ïŒèšèŒã®ã ãã³ç²åºŠæžå°å€ã ïŒ æå¹æäžéã¯çŽïŒãªããçŽ30mgïŒKgïŒæ¥ã§ã
ãè«æ±é ïŒèšèŒã®ã ãã³ç²åºŠæžå°å€ã ïŒ åèšé²åŸ¡ãããã¡ã«ã«ããåºãå«ãååç©ã¯
åŒH2NïŒCH2ïŒ3NHïŒCH2ïŒ2SPO3H2ãæããè«æ±
é ïŒèšèŒã®ã ãã³ç²åºŠæžå°å€ã
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/062,503 US4424216A (en) | 1979-07-31 | 1979-07-31 | Method for the reduction of mucin viscosity |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5622729A JPS5622729A (en) | 1981-03-03 |
JPH0223526B2 true JPH0223526B2 (ja) | 1990-05-24 |
Family
ID=22042912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11162379A Granted JPS5622729A (en) | 1979-07-31 | 1979-08-31 | Mucin viscosity reducing agent |
Country Status (2)
Country | Link |
---|---|
US (1) | US4424216A (ja) |
JP (1) | JPS5622729A (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU574360B2 (en) * | 1983-05-13 | 1988-07-07 | Reichert, D. | Antisnoring agent |
GB8327561D0 (en) * | 1983-10-14 | 1983-11-16 | Ici Plc | Contraceptive methods |
US5290813A (en) * | 1987-06-04 | 1994-03-01 | Massachusetts Institute Of Technology | Chemical prevention or reversal of cataract by phase separation inhibitors |
US5401880A (en) * | 1987-06-04 | 1995-03-28 | Oculon Corporation | Chemical prevention or reversal of cataract by phase separation inhibitors |
US5338545A (en) * | 1987-06-04 | 1994-08-16 | Oculon Corporation | Chemical prevention or reversal of cataract by phase separation inhibitors |
US5091421A (en) * | 1987-06-04 | 1992-02-25 | Massachusetts Institute Of Technology | Chemical prevention or reversal of cataract by phase separation inhibitors |
DE3883712T2 (de) * | 1987-06-04 | 1993-12-16 | Massachusetts Inst Technology | Chemisches verhindern oder rÌckgÀngigmachen von star-erkrankungen durch phasentrennungsinhibitoren. |
US5292497A (en) * | 1987-12-22 | 1994-03-08 | U.S. Bioscience, Inc. | Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate |
AU629533B2 (en) * | 1987-12-22 | 1992-10-08 | U.S. Bioscience, Inc. | Improving toxicity profiles in chemotherapy |
US4927850A (en) * | 1988-04-08 | 1990-05-22 | Bayless Robert K | Antioxidant compositions and methods for ameliorating inflammatory symptoms of respiratory disease |
FI84874C (fi) * | 1989-11-02 | 1992-02-10 | Valio Meijerien | Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den. |
US5238683A (en) * | 1989-11-24 | 1993-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Aerosol preparation of glutathione and a method for augmenting glutathione level in lungs |
US5298499A (en) * | 1991-07-05 | 1994-03-29 | Research Triangle Institute | S-2-(substituted ethylamino)ethyl phosphorothioates |
US5424471A (en) | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
SG47101A1 (en) * | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
US5508269A (en) * | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
GB9422991D0 (en) * | 1994-11-15 | 1995-01-04 | Cortecs Ltd | Analytical method |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6407278B2 (en) | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US7629333B2 (en) * | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
JP3909491B2 (ja) | 2002-09-20 | 2007-04-25 | ïœïœæ ªåŒäŒç€Ÿ | é ãã¹ã©ã€ããã¡ã¹ããŒçšã¹ã©ã€ã㌠|
EP3463278B1 (en) * | 2016-05-29 | 2020-10-28 | Scientis SA | Use of thiophosphate derivatives as skin depigmenting agents |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS535112A (en) * | 1976-03-08 | 1978-01-18 | Santen Pharmaceutical Co Ltd | New cysteine derivatives |
JPS545916A (en) * | 1977-06-17 | 1979-01-17 | Santen Pharmaceutical Co Ltd | Novel cystein derivative |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892824A (en) | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
-
1979
- 1979-07-31 US US06/062,503 patent/US4424216A/en not_active Expired - Lifetime
- 1979-08-31 JP JP11162379A patent/JPS5622729A/ja active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS535112A (en) * | 1976-03-08 | 1978-01-18 | Santen Pharmaceutical Co Ltd | New cysteine derivatives |
JPS545916A (en) * | 1977-06-17 | 1979-01-17 | Santen Pharmaceutical Co Ltd | Novel cystein derivative |
Also Published As
Publication number | Publication date |
---|---|
US4424216A (en) | 1984-01-03 |
JPS5622729A (en) | 1981-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0223526B2 (ja) | ||
US4708952A (en) | Method of treatment of the infectious and viral diseases by one time interference | |
AU656212B2 (en) | Asialoglycoprotein-conjugated medicinal agent | |
Holtzman et al. | Copper intoxication: report of a case with observations on ceruloplasmin | |
Smolin et al. | A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis | |
EP1369119B1 (en) | Il-12 expression controlling agents | |
US20230241095A1 (en) | Partially desulfated heparin for treating coronaviral infections | |
Murphy et al. | A case of poisoning with mercuric chloride | |
Erwteman et al. | Interstitial pulmonary fibrosis: a new side effect of practolol. | |
Crawhall et al. | Dissolution of cystine stones during D-penicillamine treatment of a pregnant patient with cystinuria | |
US5603932A (en) | Receptor of the minor human rhinovirus receptor group | |
CA1157774A (en) | Method for the reduction of mucin viscosity | |
Stephens et al. | The treatment of cystinuria with N-acetyl-D-penicillamine, a comparison with the results of D-penicillamine treatment | |
Flippin et al. | Sulfapyridine and sulfathiazole therapy in pneumococcic pneumonia | |
JPH01132526A (ja) | è¬å€çµæç© | |
US4978661A (en) | Use of 6-halo-4-quinolone compounds and pharmaceutical compositions thereof for the preparation of a medicament for the therapeutical application in rheumatoid arthritis | |
JPWO2002102361A1 (ja) | ãã³ã»ã³ã¹å€ç°ã«èµ·å ããçŸæ£ã®æ²»çè¬ | |
US5646182A (en) | Methods for treating autoimmune diseases | |
EP0228239B1 (en) | Preparation of a medicament for arthritis and rheumatism | |
JP3769045B2 (ja) | æççå€ | |
Clark-Price et al. | Use of dapsone in the treatment of Pneumocystis carinii pneumonia in a foal | |
JPH01502268A (ja) | ã¢ããã°ãªã³ã·ãèªå è èæ¯ã«å¯Ÿããä¿è· | |
JPH05186341A (ja) | ã·ã¹ãã³å°¿çæ²»çå€ | |
STRAUSS JR et al. | BAL treatment of toxic reactions to gold: a review of the literature and report of two cases | |
JP4627580B2 (ja) | èçŸæ£åŠçœ®å€ |